Bronchiolitis — Additional Treatment Considerations — Clinical Pathway: Emergency and Inpatient
Additional Treatment Considerations
May be considered in infants with significant respiratory distress that is not alleviated sufficiently by supportive care interventions.
|Albuterol||Studies have NOT demonstrated a consistent benefit for albuterol treatment in infants with typical bronchiolitis. An albuterol trial may be considered in children with features suggestive of possible asthma (recurrent wheezing, age > 12 months, prior inhaled corticosteroid use).
Albuterol should NOT be continued if the child does not respond to test dose.